Anti-RSPO1 antibodies
AssigneeOncoMed Pharmaceuticals, Inc.
InventorsAustin L. Gurney, Fumiko Takada Axelrod, Timothy Charles Hoey, Cecile Chartier-Courtaud
Life of this patent
Estimating the term…
Abstract
The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
Claims15
An isolated antibody that specifically binds human R-spondin 1 (RSPO1), wherein the antibody comprises:
- (a) a heavy chain CDR1 comprising TGYTMH (SEQ ID NO:12), a heavy chain CDR2 comprising GINPNNGGTTYNQNFKG (SEQ ID NO:13), and a heavy chain CDR3 comprising KEFSDGYYFFAY (SEQ ID NO:14);
- and
- (b) a light chain CDR1 comprising KASQDVIFAVA (SEQ ID NO:15), a light chain CDR2 comprising WASTRHT (SEQ ID NO:16), and a light chain CDR3 comprising QQHYSTPW (SEQ ID NO:17).
An isolated antibody that specifically binds human R-spondin 1 (RSPO1), which comprises:
- (a) a heavy chain variable region comprising SEQ ID NO:10;
- and
- (b) a light chain variable region comprising SEQ ID NO:11.
A hybridoma cell line having ATCC deposit number PTA-11970.
Dependencies are inferred from the claim text.